Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study evaluating efficacy of vemurafenib, ipilimumab and dabrafenib in patients with advanced skin melanoma in real world

Trial Profile

A retrospective study evaluating efficacy of vemurafenib, ipilimumab and dabrafenib in patients with advanced skin melanoma in real world

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Dabrafenib (Primary) ; Ipilimumab (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2018 Results (n=1170) published in the European Journal of Clinical Pharmacology
    • 05 Sep 2018 New trial record
    • 01 Sep 2018 Results published in the Journal of the European Academy of Dermatology and Venereology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top